Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Coraline Dumenil

Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma

Journal of Thoracic Oncology

English

Circulating Tumor DNA Evaluated by Next-Generation Sequencing Is Predictive of Tumor Response and Prolonged Clinical Benefit With Nivolumab in Advanced Non-Small Cell Lung Cancer

English

Predictive Role of Plasmatic Biomarkers in Advanced Non-Small Cell Lung Cancer Treated by Nivolumab

English

Plasma Biomarkers and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: New Tools for Better Patient Selection?

English

Molecular Characterization of Circulating Tumor Cells in Lung Cancer: Moving Beyond Enumeration

Oncotarget

Oncology

2017

English

Clinical Factors Associated With Early Progression and Grade 3–4 Toxicity in Patients With Advanced Non-Small-Cell Lung Cancers Treated With Nivolumab

PLoS ONE

Multidisciplinary

2018

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Coraline Dumenil

Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma

Circulating Tumor DNA Evaluated by Next-Generation Sequencing Is Predictive of Tumor Response and Prolonged Clinical Benefit With Nivolumab in Advanced Non-Small Cell Lung Cancer

Predictive Role of Plasmatic Biomarkers in Advanced Non-Small Cell Lung Cancer Treated by Nivolumab

Plasma Biomarkers and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: New Tools for Better Patient Selection?

Molecular Characterization of Circulating Tumor Cells in Lung Cancer: Moving Beyond Enumeration

Clinical Factors Associated With Early Progression and Grade 3–4 Toxicity in Patients With Advanced Non-Small-Cell Lung Cancers Treated With Nivolumab